 |
3 Diseases |  |
0 Trials |
|
0 Trials |  |
54 News |  |
- Vasomera (pemziviptadil) / PhaseBio Pharma
Phase classification: Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF (clinicaltrials.gov) - Jul 14, 2022
P2, N=29, Completed, Sponsor: PhaseBio Pharmaceuticals Inc.
Phase classification: P2a --> P2
- ||| Vasomera (pemziviptadil) / PhaseBio Pharma
Trial termination: LTE: Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (clinicaltrials.gov) - Feb 22, 2022
P2, N=25, Terminated, Sponsor: PhaseBio Pharmaceuticals Inc.
Phase classification: P2a --> P2 Suspended --> Terminated; Terminated: Study drug resupply delayed (Covid-19)
- ||| Vasomera (pemziviptadil) / PhaseBio Pharma
Trial termination: Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH (clinicaltrials.gov) - Feb 22, 2022
P2, N=35, Terminated, Sponsor: PhaseBio Pharmaceuticals Inc.
Suspended --> Terminated; Terminated: Study drug resupply delayed (Covid-19) Suspended --> Terminated; Terminated: Study drug resupply delayed (Covid-19)
- | Vasomera (pemziviptadil) / PhaseBio Pharma
Enrollment change, Trial suspension: Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH (clinicaltrials.gov) - Jan 11, 2022
P2, N=35, Suspended, Sponsor: PhaseBio Pharmaceuticals Inc.
Suspended --> Terminated; Terminated: Study drug resupply delayed (Covid-19) N=63 --> 35 | Recruiting --> Suspended
- | Vasomera (pemziviptadil) / PhaseBio Pharma
Enrollment change, Trial completion date, Trial suspension, Trial primary completion date: LTE: Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (clinicaltrials.gov) - Jan 11, 2022
P2, N=25, Suspended, Sponsor: PhaseBio Pharmaceuticals Inc.
N=63 --> 35 | Recruiting --> Suspended N=63 --> 25 | Trial completion date: Feb 2024 --> Jan 2022 | Recruiting --> Suspended | Trial primary completion date: Jan 2024 --> Jan 2022
- ||| Vasomera (pemziviptadil) / PhaseBio Pharma
P2b data: $PHAS voluntarily ending Phase 2b trial of pemziviptadil in pulmonary arterial hypertension (PAH) (Twitter) - Dec 21, 2021
- ||||| Vasomera (pemziviptadil) / PhaseBio Pharma
Trial termination: VANGARD: Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). (clinicaltrials.gov) - Dec 11, 2020
P2, N=54, Terminated, Sponsor: PhaseBio Pharmaceuticals Inc.
N=63 --> 25 | Trial completion date: Feb 2024 --> Jan 2022 | Recruiting --> Suspended | Trial primary completion date: Jan 2024 --> Jan 2022 Active, not recruiting --> Terminated; Company no longer pursing indication
- ||| Vasomera (pemziviptadil) / PhaseBio Pharma
Enrollment closed, Enrollment change: VANGARD: Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). (clinicaltrials.gov) - Nov 12, 2020
P2, N=54, Active, not recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
Active, not recruiting --> Terminated; Company no longer pursing indication Recruiting --> Active, not recruiting | N=210 --> 54
- ||| Vasomera (pemziviptadil) / PhaseBio Pharma
Enrollment open: Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH (clinicaltrials.gov) - Nov 6, 2020
P2, N=63, Recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
Recruiting --> Active, not recruiting | N=210 --> 54 Active, not recruiting --> Recruiting
- Vasomera (pemziviptadil) / PhaseBio Pharma
[VIRTUAL] Augmentation of Vasoactive Intestinal Peptide Signaling Prevents the Development of Duchenne Muscular Dystrophy-Associated Cardiomyopathy Through Inhibition of NF-κB Signaling (OnDemand) - Oct 10, 2020 - Abstract #AHA2020AHA_4793;
Utilizing a genetically modified form of VIP (PB1046) targeting cardiomyocytes, we hypothesized that augmentation of VIP signaling prevents the development of DMD-associated cardiomyopathy through inhibition of NF-κB...The molecular mechanism underlying the benefits of VIP signaling suggests an upregulation of cAMP-CREB signaling with downregulation of NF-kB signaling leading to inhibition of inflammation and fibrosis within drug-treated DMD hearts. VIP signaling in DMD may serve as a new therapeutic target for the treatment of DMD-associated cardiomyopathy.
- Vasomera (PB1046) / PhaseBio Pharma
[VIRTUAL] LONG-ACTING VIP ANALOGUE PB1046 REDUCES DISEASE PROGRESSION AND CORRECTS F508DEL-CFTR FUNCTION IN C57BL/6 MICE LUNG AND DUODENUM () - Oct 7, 2020 - Abstract #NACFC2020NACFC_481;
Support by PhaseBio Pharmaceuticals Inc. and Cystic Fibrosis Foundation.
- || Vasomera (pemziviptadil) / PhaseBio Pharma
Enrollment closed: Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH (clinicaltrials.gov) - Sep 9, 2020
P2, N=63, Active, not recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
and Cystic Fibrosis Foundation. Recruiting --> Active, not recruiting
- |||| Vasomera (pemziviptadil) / PhaseBio Pharma
Enrollment open: VANGARD: Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). (clinicaltrials.gov) - Jul 10, 2020
P2, N=210, Recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Vasomera (pemziviptadil) / PhaseBio Pharma
New P2 trial: VANGARD: Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). (clinicaltrials.gov) - Jun 15, 2020
P2, N=210, Not yet recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
- || Vasomera (pemziviptadil) / PhaseBio Pharma
Trial completion date, Trial primary completion date: Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH (clinicaltrials.gov) - Feb 5, 2020
P2, N=63, Recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
Not yet recruiting --> Recruiting Trial completion date: Jan 2020 --> Dec 2021 | Trial primary completion date: Jan 2020 --> Dec 2021
- | Vasomera (pemziviptadil) / PhaseBio Pharma
Trial completion, Enrollment change: A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH (clinicaltrials.gov) - Oct 7, 2019
P1, N=3, Completed, Sponsor: PhaseBio Pharmaceuticals Inc.
Trial completion date: Jan 2020 --> Dec 2021 | Trial primary completion date: Jan 2020 --> Dec 2021 Active, not recruiting --> Completed | N=10 --> 3
- ||| Vasomera (pemziviptadil) / PhaseBio Pharma
Enrollment open: LTE: Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (clinicaltrials.gov) - Apr 11, 2019
P2, N=64, Recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
Active, not recruiting --> Completed | N=10 --> 3 Not yet recruiting --> Recruiting
- | Vasomera (pemziviptadil) / PhaseBio Pharma
Trial completion date, Trial primary completion date: A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH (clinicaltrials.gov) - Mar 20, 2019
P1, N=10, Active, not recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
Not yet recruiting --> Recruiting Trial completion date: Jan 2019 --> Jun 2019 | Trial primary completion date: Jan 2019 --> Jun 2019
- |||| Vasomera (pemziviptadil) / PhaseBio Pharma
New P2 trial: LTE: Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (clinicaltrials.gov) - Jan 7, 2019
P2, N=64, Not yet recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
- | Vasomera (pemziviptadil) / PhaseBio Pharma
Trial primary completion date: A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH (clinicaltrials.gov) - Dec 19, 2018
P1, N=10, Active, not recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
Trial completion date: Jan 2019 --> Jun 2019 | Trial primary completion date: Jan 2019 --> Jun 2019 Trial primary completion date: Oct 2018 --> Jan 2019
- | Vasomera (pemziviptadil) / PhaseBio Pharma
Enrollment closed: A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH (clinicaltrials.gov) - Sep 5, 2018
P1, N=10, Active, not recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
Trial primary completion date: Oct 2018 --> Jan 2019 Recruiting --> Active, not recruiting
- | Vasomera (pemziviptadil) / PhaseBio Pharma
Enrollment open: Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH (clinicaltrials.gov) - Aug 9, 2018
P2, N=63, Recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Vasomera (pemziviptadil) / PhaseBio Pharma
New P2 trial: Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH (clinicaltrials.gov) - Jun 13, 2018
P2, N=63, Not yet recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
- | Vasomera (pemziviptadil) / PhaseBio Pharma
Trial completion: Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF (clinicaltrials.gov) - Mar 30, 2018
P2a, N=29, Completed, Sponsor: PhaseBio Pharmaceuticals Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Vasomera (pemziviptadil) / PhaseBio Pharma
Trial completion date, Trial primary completion date: A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH (clinicaltrials.gov) - Feb 28, 2018
P1, N=10, Recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
Active, not recruiting --> Completed Trial primary completion date: Feb 2018 --> Aug 2018 | Trial completion date: Feb 2018 --> Sep 2018
- | Vasomera (pemziviptadil) / PhaseBio Pharma
Enrollment closed: Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF (clinicaltrials.gov) - Nov 6, 2017
P2a, N=29, Active, not recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
Trial primary completion date: Feb 2018 --> Aug 2018 | Trial completion date: Feb 2018 --> Sep 2018 Recruiting --> Active, not recruiting
- Vasomera (pemziviptadil) / PhaseBio Pharma
New P1 trial: A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH (clinicaltrials.gov) - Oct 20, 2017
P1, N=10, Recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
- Vasomera (pemziviptadil) / PhaseBio Pharma
Trial primary completion date: Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF (clinicaltrials.gov) - Sep 27, 2017
P2a, N=28, Recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2017 --> Nov 2017
- Vasomera (pemziviptadil) / PhaseBio Pharma
Trial primary completion date: Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF (clinicaltrials.gov) - Nov 18, 2016
P2a, N=28, Recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
Trial primary completion date: Jun 2017 --> Nov 2017 Trial primary completion date: Feb 2017 --> Jun 2017
- | Vasomera (pemziviptadil) / PhaseBio Pharma
Enrollment open: Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF (clinicaltrials.gov) - Jul 21, 2016
P2a, N=28, Recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
Trial primary completion date: Feb 2017 --> Jun 2017 Not yet recruiting --> Recruiting
- | Vasomera (pemziviptadil) / PhaseBio Pharma
New P2a trial: Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF (clinicaltrials.gov) - Jun 22, 2016
P2a, N=28, Not yet recruiting, Sponsor: PhaseBio Pharmaceuticals Inc.
- Vasomera (pemziviptadil) / PhaseBio Pharma
Enrollment change: Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera (clinicaltrials.gov) - Apr 7, 2014
P1, N=20, Completed, Sponsor: PhaseBio Pharmaceuticals Inc.
Not yet recruiting --> Recruiting N=32 --> 20
- | Vasomera (pemziviptadil) / PhaseBio Pharma
Trial completion: Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera (clinicaltrials.gov) - Apr 7, 2014
P1, N=20, Completed, Sponsor: PhaseBio Pharmaceuticals Inc.
N=32 --> 20 Active, not recruiting --> Completed
- | Vasomera (pemziviptadil) / PhaseBio Pharma
New P1 trial: Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera (clinicaltrials.gov) - Jun 6, 2013
P1, N=20, Completed, Sponsor: PhaseBio Pharmaceuticals Inc.
- ||| Vasomera (pemziviptadil) / PhaseBio Pharma
Trial completion: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension (clinicaltrials.gov) - Jan 2, 2013
P1, N=68, Completed, Sponsor: PhaseBio Pharmaceuticals Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Vasomera (pemziviptadil) / PhaseBio Pharma
New P1 trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension (clinicaltrials.gov) - Jan 30, 2012
P1, N=68, Completed, Sponsor: PhaseBio Pharmaceuticals Inc.